Looking for the next step in obesity pharmacotherapies, the concept of combining entero-pancreatic hormones for obesity treatment was supported by the marked WL, sustained weight maintenance, and metabolic benefits observed with BS, which increase multiple gut hormone levels [9,10,11,12,13,14]
It reduces blood glucose by simultaneously stimulating insulin secretion, which is why it is effective in Type II and not Type I diabetes, and lowers glucagon secretion
This means that quality, consistency and safety depend heavily on the clinical oversight involved
Maintain minimum dose spacing: 48 hours for semaglutide and 72 hours for tirzepatide
15 Phase II trials targeting MASH have shown that treatment with SEMA 0.4 mg daily for 72 weeks resulted in more patients with liver fibrosis stage F2/F3 achieving improvement in MASH without progression of liver fibrosis (odds ratio = 6.87, 95% CI = 2.6017.63) compared to placebo
These clinical elements fall outside the typical primary care scope